Theseus Pharmaceuticals Exploring Strategic Alternatives

DENVER, Colo., Nov 14, 2023 ( Theseus Pharmaceuticals, Inc.  (NASDAQ:THRX) stated, after yesterday’s market close, that it is exploring strategic alternatives to maximize shareholder value.

Theseus Pharmaceuticals is trading at $2.79, up $0.65 (+30.37%) on 623.4K premarket shares.

Its 52-week range is $2.05 to 14.7672. It set a new 52-week low yesterday and is already trading at a new one month high. It just crossed the $2.72 resistance level and has $2.85 in its sights. Its setup is favorable to take out more resistance levels, if its trading volume can strengthen,.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.

Please go to or for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.